

World Journal of *Gastroenterology*

World J Gastroenterol 2024 December 28; 30(48): 5104-5224



EDITORIAL

- 5104 Bidirectional relationship between gastrointestinal cancer and depression: The key is in the microbiota-gut-brain axis
Priego-Parra BA, Remes-Troche JM

ORIGINAL ARTICLE**Retrospective Study**

- 5111 Image detection method for multi-category lesions in wireless capsule endoscopy based on deep learning models
Xiao ZG, Chen XQ, Zhang D, Li XY, Dai WX, Liang WH
- 5130 Prognostic value of preoperative systemic immune-inflammation index/albumin for patients with hepatocellular carcinoma undergoing curative resection
Chen KL, Qiu YW, Yang M, Wang T, Yang Y, Qiu HZ, Sun T, Wang WT

Clinical Trials Study

- 5152 Efficacy and safety of rebamipide/nizatidine in patients with erosive gastritis: A randomized, multicenter, phase 4 study
Kang D, Choi MG, Shim KN, Jung HK, Nam SJ, Park JH, Kim SG, Kim NH, Hong SJ, Jeon TJ, Chung JI, Lee HL, Lee JY, Kim TO, Lee CM, Kim SM, Kim JH, Kim JE, Moon JS, Kim HD, Lee WS, Park HJ

Observational Study

- 5162 Link between pharyngeal acid reflux episodes and the effectiveness of proton pump inhibitor therapy
Chen YY, Wang CC, Chuang CY, Tsou YA, Peng YC, Chang CS, Lien HC

Basic Study

- 5174 N6-methyladenosine-modified long non-coding RNA *KIF9-AS1* promotes stemness and sorafenib resistance in hepatocellular carcinoma by upregulating *SHOX2* expression
Yu Y, Lu XH, Mu JS, Meng JY, Sun JS, Chen HX, Yan Y, Meng K

LETTER TO THE EDITOR

- 5191 Advancing early diagnosis of inflammatory bowel disease: A call for enhanced efforts
He SB, Hu B
- 5194 Reevaluation of *Helicobacter pylori*'s role in esophageal carcinoma: A call for comprehensive research
Omer JJ, Habtemariam AH
- 5198 Small cell lung carcinoma metastatic to the stomach: Commonly overlooked, limited treatment options
Moyana TN

- 5205** GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis
Singh A, Sohal A, Batta A
- 5212** Role of *Candida* species in pathogenesis, immune regulation, and prognostic tools for managing ulcerative colitis and Crohn's disease
Patnaik S, Durairajan SSK, Singh AK, Krishnamoorthi S, Iyaswamy A, Mandavi SP, Jeewon R, Williams LL
- 5221** *Calculus bovis* hijacks the tumor microenvironment in liver cancer cells in a multifaceted approach: A falling row of dominoes
Farhat SG, Karam K

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Angela Peltec, PhD, Associate Professor, Department of Internal Medicine, Discipline of Gastroenterology, State University of Medicine and Pharmacy "Nicolae Testemitanu", Chishinev 2019, Moldova. apeltec@yahoo.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for WJG as 4.3; Quartile: Q1. The WJG's CiteScore for 2023 is 7.8.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Xiao-Mei Zheng*; Production Department Director: *Xiang Li*; Cover Editor: *Jia-Ru Fan*.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Jian-Gao Fan (Chronic Liver Disease)

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

December 28, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University
Biliary Tract Disease Institute, Fudan University

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

POLICY OF CO-AUTHORS

<https://www.wjgnet.com/bpg/GerInfo/310>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER'S OFFICIAL WEBSITE

<https://www.shca.org.cn>
<https://www.zs-hospital.sh.cn>



Advancing early diagnosis of inflammatory bowel disease: A call for enhanced efforts

Shu-Bei He, Bing Hu

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade B

Novelty: Grade B

Creativity or Innovation: Grade B

Scientific Significance: Grade B

P-Reviewer: Su LJ

Received: July 30, 2024

Revised: September 25, 2024

Accepted: November 8, 2024

Published online: December 28, 2024

Processing time: 122 Days and 1.1 Hours



Shu-Bei He, Bing Hu, Department of Gastroenterology and Hepatology/Medical Engineering Integration Laboratory of Digestive Endoscopy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Corresponding author: Bing Hu, MD, Professor, Department of Gastroenterology and Hepatology/Medical Engineering Integration Laboratory of Digestive Endoscopy, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Wuhou District, Chengdu 610041, Sichuan Province, China. hulingnj@163.com

Abstract

The diagnosis of inflammatory bowel disease (IBD) is complicated by its nonspecific clinical presentation and the limited accuracy of existing biomarker tests, frequently resulting in significant delays from the time of symptom onset to the achievement of a definitive diagnosis. Thus, improving the early identification of IBD remains a crucial focus for gastroenterologists. Blüthner *et al* innovatively utilized medical data from German IBD patients to investigate risk factors contributing to these diagnostic delays. However, certain methodological limitations in the study have impacted data extraction and interpretation, underscoring the need for more comprehensive analyses to validate these findings.

Key Words: Diagnostic delay; Early identification; Inflammatory bowel disease; Crohn's disease; Ulcerative colitis

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Achieving an early diagnosis is essential for minimizing complications and optimizing the effectiveness of therapeutic interventions in patients with inflammatory bowel disease. Through an extensive questionnaire survey, Blüthner *et al* obtained significant insights that enhanced the diagnostic protocols for inflammatory bowel disease. However, further validation and refinement of these insights are needed to ensure their reliability and practical applicability in clinical settings.

Citation: He SB, Hu B. Advancing early diagnosis of inflammatory bowel disease: A call for enhanced efforts. *World J Gastroenterol* 2024; 30(48): 5191-5193

URL: <https://www.wjgnet.com/1007-9327/full/v30/i48/5191.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v30.i48.5191>

TO THE EDITOR

The accurate and timely identification of patients with inflammatory bowel disease (IBD) is crucial for optimizing short-term symptom management and improving long-term outcomes. We read with great interest the recent article by Blüthner *et al*[1], which reported a prospective study using a 16-item questionnaire to identify risk factors contributing to prolonged diagnostic times in a German IBD cohort. However, several aspects of the study warrant further investigation.

Firstly, Table 1 illustrates that the total diagnostic period for patients with Crohn's disease (CD) exceeds that for ulcerative colitis (UC), especially during the physician-led diagnostic phase. This disparity primarily arises from the vague and nonspecific symptoms of CD, as well as its extraintestinal manifestations, which often resemble those observed in various other medical conditions. To further clarify these findings, investigating the impact of commonly misdiagnosed conditions - such as functional gastrointestinal disorders[2], intestinal tuberculosis[3], intestinal lymphoma[4], and Behçet's disease[5] - on these diagnostic delays is advisable. An in-depth examination would enhance the understanding of the complex array of diseases that must be differentiated from CD within the German health care system, thus improving physician awareness and vigilance. Such insights could also aid in the development of comprehensive diagnostic tools that more accurately predict IBD in targeted patient populations.

Secondly, Table 2 reveals that some participants were diagnosed before 2000, yet they participated in a prospective survey conducted between 2012 and 2022. This significant time gap may lead to recall bias among patients completing questionnaires decades after their initial diagnosis of IBD, potentially compromising the accuracy of key disease-specific factors such as patient wait times, medical history, and symptom severity. To improve the reliability of the research findings, we recommend conducting follow-up assessments at the initial visit for patients suspected of having IBD, using data that have been carefully recorded by physicians. This approach ensures that the data are contemporaneous and minimizes the risk of recall errors.

Thirdly, in their univariate analysis, the authors used the year 2000 as a cutoff to categorize patients on the basis of their year of diagnosis and concluded that the timing of diagnosis was not significantly associated with delays in diagnosing IBD. However, long time-span surveys inherently face challenges, including the need to account for evolving health care paradigms and changing socioeconomic landscapes that affect disease diagnoses. Therefore, a more detailed stratified analysis across different diagnostic periods is recommended to control for these confounding factors more effectively.

In summary, we commend the authors for their pioneering efforts in the early diagnosis and management of IBD patients in Germany. We also acknowledge the crucial roles of recognizing disease-specific symptoms and employing rapid diagnostic tools in shortening the diagnostic process. We look forward to further significant contributions from researchers in this field.

FOOTNOTES

Author contributions: He SB wrote the original draft; Hu B contributed to conceptualization, writing, reviewing and editing; He SB and Hu B participated in drafting the manuscript; and all authors have read and approved the final version of the manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country of origin: China

ORCID number: Bing Hu 0000-0002-9898-8656.

S-Editor: Wang JJ

L-Editor: A

P-Editor: Zheng XM

REFERENCES

- 1 **Blüthner E**, Dehe A, Büning C, Siegmund B, Prager M, Maul J, Krannich A, Preiß J, Wiedenmann B, Rieder F, Khedraki R, Tacke F, Sturm A, Schirbel A. Diagnostic delay in inflammatory bowel diseases in a German population. *World J Gastroenterol* 2024; **30**: 3465-3478 [PMID: 39156497 DOI: 10.3748/wjg.v30.i29.3465]
- 2 **Aziz I**, Simrén M. The overlap between irritable bowel syndrome and organic gastrointestinal diseases. *Lancet Gastroenterol Hepatol* 2021; **6**: 139-148 [PMID: 33189181 DOI: 10.1016/S2468-1253(20)30212-0]
- 3 **Kedia S**, Das P, Madhusudhan KS, Dattagupta S, Sharma R, Sahni P, Makharia G, Ahuja V. Differentiating Crohn's disease from intestinal tuberculosis. *World J Gastroenterol* 2019; **25**: 418-432 [PMID: 30700939 DOI: 10.3748/wjg.v25.i4.418]
- 4 **Zhang TY**, Lin Y, Fan R, Hu SR, Cheng MM, Zhang MC, Hong LW, Zhou XL, Wang ZT, Zhong J. Potential model for differential diagnosis between Crohn's disease and primary intestinal lymphoma. *World J Gastroenterol* 2016; **22**: 9411-9418 [PMID: 27895429 DOI: 10.3748/wjg.v22.i42.9411]
- 5 **Valenti S**, Gallizzi R, De Vivo D, Romano C. Intestinal Behçet and Crohn's disease: two sides of the same coin. *Pediatr Rheumatol Online J* 2017; **15**: 33 [PMID: 28427473 DOI: 10.1186/s12969-017-0162-4]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: office@baishideng.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

